Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor.
PD-1/PD-L1
VEGF
VEGFR
acquired resistance
immune-checkpoint inhibitors
mTOR
predictive markers
primary resistance
renal cell carcinoma
target therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Jun 2019
14 Jun 2019
Historique:
received:
29
04
2019
revised:
25
05
2019
accepted:
11
06
2019
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
19
6
2019
Statut:
epublish
Résumé
The development of new systemic agents has led us into a "golden era" of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to predict tumor response to treatment or primary and acquired resistance to systemic treatments still remain an unmet clinical need. Thanks to the availability of data provided by studies evaluating genomic assessments of the disease, this goal may no longer be out of reach. In this review, we summarize current knowledge about genomic alterations related to primary and secondary resistance to target therapy and immune-checkpoint inhibitors in RCC.
Identifiants
pubmed: 31207938
pii: cancers11060830
doi: 10.3390/cancers11060830
pmc: PMC6627706
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nature. 1999 May 20;399(6733):271-5
pubmed: 10353251
Science. 2001 Nov 2;294(5544):1102-5
pubmed: 11691993
Cancer Invest. 2002;20(3):324-32
pubmed: 12025227
J Immunol. 2002 Jul 1;169(1):469-75
pubmed: 12077278
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
J Cell Biol. 2004 Jul 19;166(2):213-23
pubmed: 15249583
Mol Cell. 2006 Apr 21;22(2):159-68
pubmed: 16603397
Physiol Rev. 2006 Oct;86(4):1179-236
pubmed: 17015488
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Cancer Cell. 2008 Dec 9;14(6):435-46
pubmed: 19061835
Cancer Cell. 2009 Jan 6;15(1):21-34
pubmed: 19111878
J Biol Chem. 2009 Mar 6;284(10):6038-42
pubmed: 19112107
Biol Cell. 2009 Sep;101(9):525-39
pubmed: 19281453
Cancer. 2009 Aug 15;115(16):3651-60
pubmed: 19526589
Lancet Oncol. 2009 Aug;10(8):757-63
pubmed: 19615940
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
J Exp Med. 2010 Sep 27;207(10):2187-94
pubmed: 20819927
Ann Oncol. 2011 Jun;22(6):1413-9
pubmed: 21131369
Scand J Urol Nephrol. 2011 Apr;45(3):190-5
pubmed: 21329481
Science. 2011 Jun 10;332(6035):1322-6
pubmed: 21659605
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S19-27
pubmed: 22821550
Cancer Immunol Immunother. 2012 Sep;61(9):1359-71
pubmed: 22833104
Lancet Oncol. 2012 Oct;13(10):1055-62
pubmed: 22959186
Clin Cancer Res. 2013 Jan 15;19(2):393-403
pubmed: 23204132
Eur J Cancer. 2013 Apr;49(6):1287-96
pubmed: 23321547
PLoS One. 2013;8(2):e54206
pubmed: 23437041
Lancet Oncol. 2013 May;14(6):552-62
pubmed: 23598172
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Biochim Biophys Acta. 2014 Apr;1845(2):221-31
pubmed: 24480319
Lancet Oncol. 2014 Mar;15(3):245-6
pubmed: 24556039
Lancet Oncol. 2014 Mar;15(3):286-96
pubmed: 24556040
J Clin Oncol. 2014 May 10;32(14):1412-8
pubmed: 24687826
Am J Surg Pathol. 2014 Dec;38(12):1588-602
pubmed: 25025441
Cancer Res Treat. 2014 Oct;46(4):339-47
pubmed: 25036572
Cancer Cell. 2014 Sep 8;26(3):319-330
pubmed: 25155756
Nat Rev Immunol. 2015 Jan;15(1):45-56
pubmed: 25534622
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Nat Rev Urol. 2015 Dec;12(12):706-12
pubmed: 26526752
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Mol Cell Biol. 2016 Jun 15;36(13):1836-55
pubmed: 27141054
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Semin Cell Dev Biol. 2017 Apr;64:98-106
pubmed: 27615548
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Ann Oncol. 2017 Jun 1;28(6):1339-1345
pubmed: 28327953
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Tumori. 2017 Sep 18;103(5):405-421
pubmed: 28497847
Expert Opin Biol Ther. 2017 Sep;17(9):1049-1052
pubmed: 28592155
J Clin Oncol. 2017 Sep 10;35(26):2993-3001
pubmed: 28644771
Eur Urol. 2017 Dec;72(6):974-983
pubmed: 28720391
Cancer Treat Rev. 2017 Sep;59:123-131
pubmed: 28818671
Oncotarget. 2017 Jul 21;8(33):55230-55245
pubmed: 28903416
Cancer Treat Rev. 2017 Nov;60:152-157
pubmed: 28992528
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur J Cancer. 2018 May;94:87-94
pubmed: 29547835
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Expert Opin Pharmacother. 2018 Jun;19(9):1021-1025
pubmed: 29851529
Cell Rep. 2018 Jun 19;23(12):3698
pubmed: 29925010
Future Oncol. 2018 Dec;14(29):2997-2999
pubmed: 30411632
Crit Rev Oncol Hematol. 2018 Dec;132:89-99
pubmed: 30447930
Lancet Oncol. 2019 Feb;20(2):179-180
pubmed: 30658937
Clin Genitourin Cancer. 2019 Apr;17(2):e339-e344
pubmed: 30704796
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Clin Drug Investig. 2019 Jun;39(6):503-519
pubmed: 30937824
Immunotherapy. 2019 May;11(7):631-643
pubmed: 30943858